Simple model stratifies liver cancer risk in non-cirrhotic chronic hepatitis C patients after viral eradication

Le résumé fourni par la source

INTRODUCTION AND OBJECTIVES: Current guidelines recommend hepatocellular carcinoma (HCC) surveillance only in cirrhotic chronic hepatitis C (CHC) patients after sustained virologic response (SVR). With the cost-effectiveness threshold for surveillance lowered to 0.7% annually, the need to extend surveillance to non-cirrhotic remains controversial. We aimed to develop and validate a simple model to stratify post-SVR HCC risk in non-cirrhotic CHC patients. MATERIALS AND METHODS: Multicenter cohort of 5741 direct-acting antiviral-treated CHC patients with pre-therapy FIB-4 < 3.25 (derivation = 1902; validation = 3839). A risk model for HCC was derived using Cox regression. RESULTS: Over a median follow-up of 3.5 years, 85 patients developed HCC. Age emerged as the key stratifier: in patients < 65 years, a composite score performed best, whereas in ≥ 65 years, AFP alone sufficed. Age ≥ 65 years was prespecified, as incidence exceeded 0.7% annual threshold. In patients < 65 years, the SFA score (male: 1, AFP ≥ 6:1, FIB-4 ≥ 2.5: 2; range: 0-4) showed strong discrimination (C-index 0.90 derivation, 0.84 validation). SFA ≥ 3 defined a high-risk group with 2.9% annual HCC incidence. In those aged ≥ 65 years, AFP ≥ 6 ng/mL alone predicted high risk (annual incidence 3.5%; C-index 0.826 derivation; 0.792 validation). AFP ≥ 6 ng/mL and FIB-4 ≥ 2.5 thresholds were identified by Youden's index in derivation and validated thereafter. CONCLUSIONS: The SFA score (for < 65 years) and AFP cut-off (for ≥ 65 years) identify a small subset of non-cirrhotic CHC patients with sufficiently high HCC risk to justify continued surveillance after SVR. This simple model supports precision HCC surveillance in an overlooked population.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.